Dupont Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Dupont Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,228	Closed	-$115K	–	1640
2022 Q2	$115K	Hold	2,228	–	–	0.01%	1154
2022 Q1	$162K	Sell	2,228 -198	-8%	-$16.8K	0.01%	1141
2021 Q4	$287K	Sell	2,426 -968	-29%	-$121K	0.01%	990
2021 Q3	$455K	Sell	3,394 -5,919	-64%	-$896K	0.01%	933
2021 Q2	$1.51M	Sell	9,313 -4,357	-32%	-$339K	0.04%	438
2021 Q1	$1.1M	Sell	13,670 -12,011	-47%	-$806K	0.03%	542
2020 Q4	$1.4M	Sell	25,681 -1,917	-7%	-$69.6K	0.03%	438
2020 Q3	$549K	Sell	27,598 -1,849	-6%	-$38.6K	0.01%	711
2020 Q2	$619K	Sell	29,447 -2,629	-8%	-$44.7K	0.01%	681
2020 Q1	$392K	Hold	32,076	–	–	0.01%	765
2019 Q4	$471K	Buy	32,076 +8,050	+34%	+$112K	0.01%	871
2019 Q3	$321K	Buy	+24,026	New	+$383K	0.01%	968

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dupont Capital Management's NTLA Position: Q3 2022 in Review

Dupont Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 2,228 shares — an estimated $115K sold.

Dupont Capital Management first reported a position in NTLA in Q3 2019 and held it in 12 quarters. The position peaked at $1.51M in Q2 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Dupont Capital Management reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
Dupont Capital Management sold 2,228 Intellia Therapeutics shares in Q3 2022, an estimated $115K.
Dupont Capital Management first reported a position in Intellia Therapeutics in Q3 2019 and held it in 12 quarters.
Dupont Capital Management's Intellia Therapeutics position peaked at $1.51M in Q2 2021.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.